EVAXION BIOTECH SP.ADS/10 Aktie

Evaxion reported a net loss of $3.7m for Q2 2026 and said its cash runway and spending plan secure operations into the second half of 2027. Investors reacted positively to progress with EVX-01 (personalized melanoma vaccine; three-year data expected in October), AML candidate EVX-04 (regulatory filing planned by end-2026) and the early glioblastoma program EVX-05. The stock rose about 5.4% in premarket trading to $3.32 but remains well below its 52-week high; management emphasizes disciplined spending and potential partnerships to further extend the runway. » Más en de.investing.com

Evaxion posted a net loss of USD 3.7 million in the second quarter, with R&D expenses of USD 2.3 million and administrative costs of USD 1.5 million. As of June 30, cash and cash equivalents stood at USD 14.0 million, sufficient to fund operations into the second half of 2027, while equity fell to USD 9.5 million. The company will present three‑year data on its personalized cancer vaccine candidate EVX-01 at the ESMO congress in October and plans to file an application for clinical testing of EVX-04 before year-end. Evaxion is also expanding its pipeline with EVX-05 against glioblastoma in collaboration with Duke University and presented data on EVX-V1 and EVX-04 at professional conferences. » Más en de.investing.com

Evaxion will present three-year data from its Phase 2 study of the personalized cancer vaccine candidate EVX-01 at the ESMO congress. The two-year data showed an objective response rate of 75% (12 of 16 patients) and four complete remissions; after two years 92% of responders remained relapse-free, and tumor reduction was documented in 15 of 16 patients. In the third year patients received EVX-01 as monotherapy following prior combined treatment with pembrolizumab, and the vaccine induced immune responses in all patients. Evaxion has a market capitalization of around $26 million, the stock is down about 35% year-to-date, analysts see price targets of $9–16 and InvestingPro rates the stock as undervalued. » Más en de.investing.com